期刊文献+

气相色谱法测定达比加群酯中10种溶剂的残留 被引量:7

Determination of Ten Solvent Residues in Dabigatran Etexilate by Gas Chromatography
下载PDF
导出
摘要 目的:建立气相色谱法检测达比加群酯中10种残留溶剂。方法:以Rtx-11.0μm)极性毛细管柱程序升温,以氮气为载气,FID为检测器,进样口温度为200℃,检测器温度为250℃,对达比加群酯中10种残留溶剂(甲醇、乙醇、乙酸乙酯、丙酮、二氯甲烷、正己烷、四氢呋喃、异辛烷、吡啶和甲苯)进行测定。结果:各残留溶剂组分均能被良好分离,各溶剂线性关系良好,精密度RSD均不超过3.50%,平均回收率为96.0%~105.0%。结论:本文建立的方法可用于达比加群酯中残留溶剂的测定。 Objective: To establish a gas chromatographic method for the determination of ten residual solvents in dabigatran etexilate. Methods: The Rtx-1(60 m × 0.32 mm × 1.0 μm) polar capillary column was used to heat up the sample. Nitrogen was used as the carrier gas, FID was used as the detector, the inlet temperature was and the detector temperature was 250 ℃. Ten residual solvents(methanol, ethanol, ethyl acetate, acetone, dichloromethane, hexane, tetrahydrofuran, isooctane, pyridine and toluene) in picarbitol ester were quantified under the above conditions. Results: The residual solvents were well separated, the linear relationships were good, the RSDs were less than 3.50%, and the average recoveries were 96.0%-105.0%. Conclusion: The method demonstrated in this paper can be used for the determination of residual solvents in dabigatran etexilate.
出处 《中国药事》 CAS 2017年第3期263-268,共6页 Chinese Pharmaceutical Affairs
关键词 气相色谱法 达比加群酯 残留溶剂 甲醇 乙醇 乙酸乙酯 丙酮 二氯甲烷 正己烷 四氢呋喃 异辛烷 吡啶 甲苯 gas chromatography dabigatran etexilate solvent residues methanol ethanol ethyl acetate acetone dichloromethane hexane tetrahydrofuran isooctane pyridine toluene
  • 相关文献

参考文献6

二级参考文献89

  • 1秦立,胡昌勤,刘文英.顶空气相色谱法测定药品中残留溶剂的影响因素考察[J].药物分析杂志,2005,25(7):823-826. 被引量:40
  • 2van RYN J, STABGIER J, HAERTI'ER S, et al. Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity[J]. Thromb Haemost, 2010, 103(6): 1116-1127.
  • 3SORBERA LA, BOZZO J, CASTANER J. Dabigatran/dabiga- tran etexilate[J]. Drugs Future, 2005, 30.(9) : 877-885.
  • 4HUGHES B. First oral warfarin alternative approved in the US[J]. Nat Rev Drug Diseov, 2010, 9(12): 903-906.
  • 5CONNOLLY SJ, EZEKOWITZ MD, YUSUF S, et al. Dabigatran versus warfarin in patients with atrial fibrillation [J]. N Engl J Med, 2009, 361(12): 1139-1151.
  • 6WIENEN W, STASSEN JM, PRIEPKE H, et al. Effects of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate, on thrombus formation and bleeding time in rats[J]. Thromb Haemost, 2007, 98(2): 333- 338.
  • 7WIENEN W, STASSEN JM, PRIEPKE H, et al. Antithrombotic and anticoagulant effects of the direct thrombin inhibitor dabigatran, and its oral prodrug, dabigatran etexilate, in a rabbit model of venous thrombosis[J]. J Thromb Haemost, 2007, 5(6) : 1237-1242.
  • 8UFER M. Comparative efficacy and safety of the novel oral anti- coagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical development[J]. Thromb Haemost, 2010, 103 (3): 572-585.
  • 9BLECH S, EBNER T, LUDWING-SCHWELLINGER E, et al. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans[J]. Drug Metab Dispos, 2008, 36(2) : 386-399.
  • 10STANGIER J, STAHLE H, RATHGEN K, et al. Pharmacokine- tics and pharrnacodynamies of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects [J]. Clin Pharmacokinet,2008, 47 (1) : 47-59.

共引文献92

同被引文献66

引证文献7

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部